Chief Executive Officer
CurrentI’m the Chairman, CEO and founder of Cellectis, a biopharmaceutical company focused on oncology. The company’s mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Cellectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN™, meganucleases and the state-of-the-art electroporation technology Pulsagile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Cellectis adoptive cancer immunotherapy for chronic and acute leukemias is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Cellectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets.I received my Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie). Then, I completed a research fellowship in the Harvard Medical School Department of Genetics. Later, while working in the Division of Molecular Medicine at Boston Children’s Hospital, I developed the first approaches to meganuclease-based human gene therapy. I have a business and management training from the HEC Business School (Challenge +). I have also been the President of the French biotechnology association France Biotech for 4 years and a half.
